Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Allogeneic stem cell transplantation (allo-SCT) for de novo Ph+ AML: a study from the French Society of Bone Marrow Transplantation and Cell Therapy

Bone Marrow Transplantation volume 50, pages 1586–1588 (2015)Cite this article

Subjects

Philadelphia chromosome incidence in primary AML (Ph+ AML) is 0.5–3%.1, 2 The reality of Ph+ AML remains controversial and to date is not described in the 2008 revision of the WHO (World Health Organization) classification as a separate entity.3 CML in myeloid blast crisis (MBC-CML) and mixed phenotype acute leukemia (MPAL) with t(9;22)(q34;q11) are differential diagnoses. Unlike CML, cases of Ph+ AML do not have a history of abnormal hemograms, lack an argument for a previous chronic phase of CML and lack basophilia or splenomegaly.4 In addition, cytogenetic and molecular abnormalities may be useful to distinguish CML from Ph+ AML5 as much as trisomy 8, trisomy 19 or isochromosome 17q, besides t(9;22) and ABL1 mutations are common additional abnormalities in MBC-CML,4, 6, 7 while Ph+ AML generally exhibits gene mutations suppressing cell differentiation (Core Binding Factor AML, NPM1) or mutations increasing cell proliferation (FLT3, RAS).3, 6, 8 Primary Ph+ AML has recently been described as a distinct AML subtype with a specific genome signature compared with CML.9 Although allogeneic stem cell transplantation (Allo-SCT) is often proposed as the curative option, the outcome of Ph+ AML treated with Allo-SCT remains unknown in the literature. The objective of the study was to compared primary Ph+ AML with others Ph+ acute leukemia (MPAL and MBC-CML). Here we wanted to present the result of a retrospective, multi-center study assessing the results of allo-HSCT in Ph+ acute leukemia patients that reported to the SFGM-TC registry between 2000 and 2012 (though ProMISe, a Project Manager Internet Server). Nineteen patients with Ph+ AML were identified in France and compared with 21 patients with Ph+ MPAL and 52 patients with MBC-CML. For AML, MPAL and MBC-CML patients, the median age per group was, respectively, 46 (range: 18–67), 36 (range: 18–52) and 36 (range: 18–63) years. Ph+ de novo AML was defined in patients with AML who do not have a history of abnormal hemograms, lack evidence of a previous chronic phase of CML and lack basophilia or splenomegaly.4 MBC-CML was defined by CML history or AML with CML features such as splenomegaly, basophilia or cytogenetic additional abnormality known to be associated with CML-MBC (as trisomy 8, trisomy 19 or isochromosome 17q).

As previously described in AML,10 patients in this study developing a chronic graft versus host disease (GvHD) have both improved overall survival and better relapse free survival. However, the present study has some limits. The retrospective nature of the study may have induced selection biases. On the other hand, it is possible to criticize the other two groups (MBC-CML and MPAL) taken for comparison. Indeed, these two groups must be differentiated from Ph+ AML in terms of treatment choice and/or response to chemotherapy. The majority of MPAL patients received lymphoblastic like therapy in contrast to patients with Ph+ AML or MBC-CML. Nevertheless, whatever the comparator arms, the present study has the merit to describe the survival of Ph+ AML patients treated with allo-SCT, which has never been done. In conclusion, our study enriches the knowledge of primary Ph+ AML, describing a promising 68% 2-years overall survival.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Keung Y-K, Beaty M, Powell BL, Molnar I, Buss, Pettenati M . Philadelphia chromosome positive myelodysplastic syndrome and acute myeloid leukemia-retrospective study and review of literature. Leuk Res 2004; 28: 579–586.

    Article  CAS  PubMed  Google Scholar 

  2. Reboursiere E, Chantepie S, Gac A-C, Reman O . Rare but authentic Philadelphia-positive acute myeloblastic leukemia: Two case reports and a literature review of characteristics, treatment and outcome. Hematol Oncol Stem Cell Ther 2015; 8: 28–33.

    Article  PubMed  Google Scholar 

  3. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwitet A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937–951.

    CAS  PubMed  Google Scholar 

  4. Soupir CP, Vergilio J-A, Dal Cin P, Muzikansky A, Kantarjian H, Jones D et al. Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis. Am J Clin Pathol 2007; 127: 642–650.

    Article  PubMed  Google Scholar 

  5. Cuneo A, Ferrant A, Michaux JL, Demuynck H, Boogaerts M, Louwagie A et al. Philadelphia chromosome-positive acute myeloid leukemia: cytoimmunologic and cytogenetic features. Haematologica 1996; 81: 423–427.

    CAS  PubMed  Google Scholar 

  6. Konoplev S, Yin CC, Kornblau SM, Kantarjian H, Konopleva M, Andreeff M et al. Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia. Leuk Lymphoma 2013; 54: 138–144.

    Article  CAS  PubMed  Google Scholar 

  7. Watkins DB, Hughes TP, White DL, D'Andrea RJ . NPM1 mutations occur rarely or not at all in chronic myeloid leukaemia patients in chronic phase or blast crisis. Leukemia 2013; 27: 489–490.

    Article  CAS  PubMed  Google Scholar 

  8. Bacher U, Haferlach T, Alpermann T, Zenger M, Hochhaus A, Beelen DW et al. Subclones with the t(9;22)/BCR-ABL1 rearrangement occur in AML and seem to cooperate with distinct genetic alterations. Br J Haematol 2011; 152: 713–720.

    Article  PubMed  Google Scholar 

  9. Nacheva EP, Grace CD, Brazma D, Gancheva M, Howard-Reeves J, Rai L et al. Does BCR/ABL1 positive acute myeloid leukaemia exist? Br J Haematol 2013; 161: 541–550.

    Article  CAS  PubMed  Google Scholar 

  10. Baron F, Labopin M, Niederwieser D, Vigouroux S, Cornelissen JJ, Malm C et al. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. Leukemia 2012; 26: 2462–2468.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut d’Hématologie de Basse-Normandie, Centre Hospitalier Universitaire, Côte de Nacre, Caen Cedex, France

    S P Chantepie & O Reman

  2. Service d’hématologie, Centre Hospitalier Lyon Sud, Pierre-Bénite, France

    M Michallet

  3. Service d’hématologie, Institut Paoli-Calmettes, Marseille, France

    D Blaise

  4. INSERM U 955, Hôpital Henri-Mondor, Créteil, France

    S Maury

  5. Service d’Hématologie, CHU Jean Minjoz, Besançon, France

    E Deconinck

  6. Service d’Hématologie, Hôpital HAUT-LEVEQUE, CHU de Bordeaux, Pessac, France

    R Tabrizi

  7. Service d’Hématologie, Centre Henri Becquerel, Rouen, France

    N Contentin

  8. Hôpital Saint-Antoine, APHP, Paris, France

    M Mohty

  9. Université Pierre & Marie Curie, Paris, France

    M Mohty

  10. INSERM, UMRs 938, Paris, France

    M Mohty

  11. Service d’Hématologie, Hopital Pitié-Salpétrière, Paris, France

    S Nguyen

  12. Département d'Hématologie et Oncologie, Hôpital de Hautepierre, Strasbourg, France

    B Lioure

  13. Service d’Hématologie, Hôpital Edouard Herriot, Lyon, France

    N Raus

  14. Hematology Transplantation Unit, Hôpital Saint Louis, Paris, France

    R Peffault de Latour

  15. Greffe de moelle osseuse, Hôpital Huriez, Lille, France

    I Yakoub-Agha

Authors
  1. S P Chantepie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M Michallet
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D Blaise
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Maury
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E Deconinck
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R Tabrizi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. N Contentin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M Mohty
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. S Nguyen
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. B Lioure
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. N Raus
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. R Peffault de Latour
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. I Yakoub-Agha
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. O Reman
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of the SFGM-TC group

Corresponding author

Correspondence to S P Chantepie.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on Bone Marrow Transplantation website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chantepie, S., Michallet, M., Blaise, D. et al. Allogeneic stem cell transplantation (allo-SCT) for de novo Ph+ AML: a study from the French Society of Bone Marrow Transplantation and Cell Therapy. Bone Marrow Transplant 50, 1586–1588 (2015). https://doi.org/10.1038/bmt.2015.206

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2015.206

This article is cited by

Search

Advanced search

Quick links